We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
- Authors
Wouter W de Herder; H Rob Taal; Piet Uitterlinden; Richard A Feelders; Joop A M J L Janssen; Aart-Jan van der Lely
- Abstract
OBJECTIVES: To study whether the growth hormone (GH) response after the subcutaneous administration 50 g of octreotide (acute octreotide test) has any predictive value for long-term IGF-I normalization with Sandostatin LAR. DESIGN: Twenty four therapy-naive patients with active acromegaly were studied. RESULTS: >75% GH decrease in the acute octreotide test predicted long-term IGF-I normalization with Sandostatin LAR in 8/11 (73%) of patients. 3/13 (23%) patients with <75% GH decrease in the acute octreotide test were long-term biochemically controlled with Sandostatin LAR. Using the >75% GH reduction criterion, the sensitivity and specificity of this test for predicting long-term normalization of serum IGF-I with Sandostatin LAR treatment were 73% and 77%, respectively (positive and negative predictive values: 73% and 77%, respectively). 6/8 (75%) patients with GH suppression to levels <1.1 g/l and 9/16 (56%) patients with GH suppression to levels <2 g/l in the acute octreotide test showed normalization of serum IGF-I with long-term Sandostatin LAR treatment. The sensitivity and specificity of GH suppression <1.1 g/l for predicting of the long-term normalization of serum IGF-I with Sandostatin LAR therapy were 55% and 85%, respectively (positive and negative predictive values: 75% and 69%, respectively). The sensitivity and specificity of GH suppression <2 g/l for predicting of the long-term normalization of serum IGF-I with Sandostatin LAR therapy were 82% and 46%, respectively (positive and negative predictive values: 56% and 75%, respectively). CONCLUSION: The acute octreotide is not recommended for clinical decision making with regard to long-term treatment using the long-acting somatostatin analog Sandostatin LAR in acromegaly.
- Subjects
PITUITARY diseases; BONE diseases; DECISION making; THERAPEUTICS
- Publication
European Journal of Endocrinology, 2005, Vol 153, Issue 1, p67
- ISSN
0804-4643
- Publication type
Article
- DOI
10.1530/eje.1.01935